First Manhattan’s Aldeyra Therapeutics ALDX Stock Holding History

First Manhattan’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.7K	Hold	34,745	–	–	﹤0.01%	748
2025 Q4	$180K	Hold	34,745	–	–	﹤0.01%	706
2025 Q3	$181K	Hold	34,745	–	–	﹤0.01%	690
2025 Q2	$133K	Hold	34,745	–	–	﹤0.01%	680
2025 Q1	$200K	Hold	34,745	–	–	﹤0.01%	648
2024 Q4	$173K	Hold	34,745	–	–	﹤0.01%	659
2024 Q3	$187K	Hold	34,745	–	–	﹤0.01%	656
2024 Q2	$115K	Hold	34,745	–	–	﹤0.01%	647
2024 Q1	$114K	Hold	34,745	–	–	﹤0.01%	749
2023 Q4	$122K	Hold	34,745	–	–	﹤0.01%	730
2023 Q3	$232K	Hold	34,745	–	–	﹤0.01%	634
2023 Q2	$292K	Hold	34,745	–	–	﹤0.01%	590
2023 Q1	$345K	Hold	34,745	–	–	﹤0.01%	577
2022 Q4	$242K	Hold	34,745	–	–	﹤0.01%	654
2022 Q3	$185K	Hold	34,745	–	–	﹤0.01%	708
2022 Q2	$138K	Hold	34,745	–	–	﹤0.01%	785
2022 Q1	$154K	Hold	34,745	–	–	﹤0.01%	807
2021 Q4	$138K	Hold	34,745	–	–	﹤0.01%	818
2021 Q3	$305K	Sell	34,745 -1,001	-3%	-$9.19K	﹤0.01%	660
2021 Q2	$405K	Buy	+35,746	New	+$430K	﹤0.01%	599
2020 Q3	–	Sell	-350	Closed	-$1K	–	1324
2020 Q2	$1K	Buy	+350	New	+$1.28K	﹤0.01%	1337

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Manhattan's ALDX Position: Q1 2026 in Review

First Manhattan held its Aldeyra Therapeutics (ALDX) position steady in Q1 2026 at 34,745 shares worth $58.7K. The position accounts for ﹤0.01% of the portfolio, ranked #748.

First Manhattan first reported a position in ALDX in Q2 2020 and has held it in 21 quarters since. The position peaked at $405K in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

First Manhattan held 34,745 shares of Aldeyra Therapeutics worth $58.7K as of Q1 2026.
First Manhattan left its Aldeyra Therapeutics share count unchanged in Q1 2026.
Aldeyra Therapeutics made up ﹤0.01% of First Manhattan's portfolio in Q1 2026, its #748 holding.
First Manhattan first reported a position in Aldeyra Therapeutics in Q2 2020 and has held it in 21 quarters since.
First Manhattan's Aldeyra Therapeutics position peaked at $405K in Q2 2021.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.